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Background and Purpose: Individualized anti-epileptic drug (AED) selection in patient with epilepsy is 
crucial. However, there is no unified opinion in treating patients with drug resistant epilepsy (DRE). This 
survey aimed to make a consolidate consensus with epileptologists’ perspectives of the treatment for Korean 
DRE patients by survey responses.
Methods: The survey was conducted with Korean epilepsy experts who have experience prescribing AEDs 
via e-mail. Survey questionnaires consisted of six items regarding prescription patterns and practical 
questions in treating patients with DRE in Korea. The research period was from February 2021 to March 2021.
Results: The survey response rate was 83.3% (90/108). Most (77.8%) of the responders are neurologists. 
The proportion of patients whose seizures were not controlled by the second AED was 26.9%. The proportion 
of patients who had taken five or more AEDs is 13.9%, and those who are currently taking five or more 
AEDs are 7.3%, of which 54.5% and 37.9% reported positive effects on additional AED, respectively. The 
majority (91.1%) of respondents answered that the mechanism of action was the top priority factor when 
adding AED. Regarding data priority, responders considered that expert opinion should have the top priority, 
followed by clinical experiences, reimbursement guidelines and clinical evidence. Responders gave 64.9 
points (range from 0 to 100) about overall satisfaction on reimbursement system of Health Insurance Review 
and Assessment Service for AED.
Conclusions: This study on AED therapy for DRE patients is the first nationwide trial in Korean epilepsy 
experts. In five drug failure, the top priorities on AED selection are mechanism of action and expert opinion. 
These findings might help to achieve consensus and recognize the insight on optimal therapy of AED in 
DRE. (2021;11:72-82)
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Introduction
Epilepsy is a chronic disorder of the brain characterized by re-
current episodic attacks, epileptic seizures, and their somatic and 
psychiatric consequences.1 Epilepsy affects approximately 65 million 
people worldwide.2 The overall prevalence of treated epilepsy pa-
tients was 2.41/1,000, which is the period prevalence as of 2007. 
Gender-specific prevalence was higher in men than in women in all 
age groups. Its prevalence was the lowest in those in their 30s and 
40s, and increased from the 50s age group in men, whereas the 
prevalence was nearly constant from the 40s age group in women.3
Anti-epileptic drug (AED) therapy is the mainstay of epilepsy 
treatment. Current treatment of AED follows a step approach that com-
prises initial mono-therapy and subsequent secondary mono- or initial 
add-on therapy, followed by the next drug trials using either 
mono-therapy or polytherapy. A variety of AEDs have been developed 
over the past few decades. Some are under development right now. 
Recently developed AEDs are categorized as the third generation of 
AEDs. Several compounds are under clinical investigation. They will be 
introduced to the market in near future. In Korea, about 20 AED are 
available currently. A few drugs are in process of obtaining approval 
from the Korea Food & Drug Administration. Newly introduced AEDs 
show better safety profiles with new mechanisms of action. They have 
various mode of actions, including the following molecular mecha-
nisms: 1) voltage-gated channel-related mechanism including block-
ing sodium or calcium channels or opening potassium channel; 2) neu-
rotransmission-related mechanism such as modifying GABAergic or 
glutamatergic transmission; and 3) having specific molecular targets 
during synaptic vesicle transmission.4 A number of AEDs can work by 
more than one of the mechanism. However, our understanding about 
the entire prolife of AEDs’ acting mechanisms are very limited. 
Moreover, although AEDs can suppress seizure, they cannot prevent or 
cure epilepsy. Despite there are a wider range of options of AEDs, about 
one-third of patients still suffer from drug resistant epilepsy (DRE) so 
far.
DRE patients face a significant trouble with potentially devastating 
neuropsychiatric dysfunction, psychosocial issues, a reduced quality 
of life, increased comorbidities, and even sudden unexpected death 
issues.5 Thus, early diagnosis and optimal therapy of patients with 
DRE are crucial. To achieve seizure freedom, clear clinical definition 
of DRE, knowledge of biomarkers, predictors, the pathophysiologic 
mechanism of DRE, and successful new therapy should be 
implicated.6-8 The underlying mechanism of DRE across a wide 
range of clinical settings and epilepsy syndrome remains unclear, al-
though transporter hypothesis and target hypothesis have been 
suggested.4,9 An integrating concept incorporating a multifactorial 
process such as disease severity, genetic disorders, metabolic abnor-
malities, structural lesions, and network dysfunction with ongoing 
neural reorganization has been introduced.10,11 However, defining 
DRE is very difficult because the degree of intractability and the re-
sponsiveness to AED are highly variable according to the individual’s 
state and disease course.
Despite many years of research, definitions of DRE still remain op-
erational so far. An ad hoc task force of the International League 
Against Epilepsy (ILAE) defined drug resistance as “failure of ad-
equate trials of two tolerated, appropriately chosen, and used an-
ti-seizure medication schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom”.8 It appeared to 
have a high degree of interrater reliability.12,13 However, there are 
vague terms such as “failure”, “adequate trials”, and “sustained 
seizure freedom” in the ILAE definition of DRE. Moreover, the prac-
tical criterion “the two drug schedules” was formed in the era of the 
second generation of AEDs more than 20 years ago. The definition of 
DRE means that refractoriness can occur independent of the chosen 
AED. However, we are in the era of the third generation of AEDs with 
the capability of fully choosing an optimal treatment with about 20 
AEDs. In addition, newly developed AEDs have evolutionary pharma-
cokinetic profiles, revolutionary acting mechanisms, and specific syn-
drome-targeting orphan drugs. These two drug criteria might be in-
appropriate to the current therapy. The operational concept would be 
in conflict with the current knowledge of underlying mechanism of 
DRE because diversely acting AEDs can affect many molecular tar-
gets at the same time.14
Epilepsy experts in real practice struggle with diagnosis and treat-
ment of those patients in terms of patient’s explanation, clinical ap-
plication of treatment, determination of prognosis, a unified collec-
tion of patients for future research, and so on. The guidance for DRE 
patients has highlighted recent advances in patient-specific precision 
medicine.15-17 Rapidly developing method of neurogenetics and neu-
roimmunology, arterial intelligence, and big data technology can also 
be merged with AED thearpy.18,19 In the present choice of AED, dis-
ease-oriented concept in the past has been changed to a patient-ori-
ented concept that is based on comprehensive multi-dimensional as-
sessment of individual patients.
Therefore, the Drug Committee of Korean Epilepsy Society per-
formed this study to understand the perception of Korean epilepsy 
74 Journal of Epilepsy Research Vol. 11, No. 1, 2021
Copyright ⓒ 2021 Korean Epilepsy Society
A
B
Figure 1. Study design. (A) Time schedule for the survey. (B) Responder disposition and key steps involved in the survey for anti-epileptic drug medication.
experts by analyzing approaches of AED selection for DRE patients in 
consideration of clinical experience along with the magnitude and lo-
cation of the medical institution. Regarding treatment failure, the 
questions included both “two drug failure” and “five drug failure”, 
reflecting recent common polytherapy in treating DRE. It will be ben-
eficial to apply these results to real clinicians, which support them to 
achieve consensus in the treatment of DRE patients as well as to rec-
ognize the insight into DRE.
Methods
Survey participants and methods 
The survey was conducted with 108 eligible experts (neurologists, 
neurosurgeons, and pediatricians) who actively participate in the 
treatment of patients with epilepsy. They were in the drug or epi-
demiology committees of Korean epilepsy society with experience in 
prescribing AEDs or at least 1-year clinical experience of epilepsy 
clinic practice. A total of 108 eligible participants received the survey 
e-mail for approximately 2 weeks. Responding e-mails were gath-
ered within the first 2 weeks after receiving the first e-mail. Another 
2 weeks after the second e-mail were allowed for participants who 
did not respond to the first email. The survey period was from 
February 2021 to March 2021 (4-week period) (Fig. 1A). Overall, of 
108 eligible participants for the survey, 92 (85.2%) responded. 
However, responses from two (1.8%) of these 92 were not appli-
cable because they did not answer each item with the expression of 
their poor experience in DRE. Thus, responses from a total of 90 
participants were analyzed (Fig. 1B). The survey was conducted 
nationwide. The factors such as gender (male/female), subspecialty 
(neurology, pediatrics, neurosurgery), clinical experience (less than 
10 years, not less than 10 to less than 20 years, not less than 20 to 
less than 30 years, 30 years or more), hospital level (primary, secon-
dary, tertiary, quaternary),20 and region (Seoul, Gyeonggi, Chungcheong, 
Jeolla, Jeju, Gyeonsang, and Gangwon) were considered as charac-
teristics of survey respondents. 
Respondent demographics
Of subjects of the survey, males accounted for 74.4% (n=67) and 
females for 25.6% (n=23). Regarding expertise, neurology (77.8%, 
n=70) occupied the highest percentage, followed by pediatrics 
(18.9%, n=17) and neurosurgery (3.3%, n=3). The median experi-
ence of the subjects was 15.0±8.22 years (range, 1 year to 34 years). 
Subjects who had ≥10 years but <20 years of experience accounted 
for 41.1% (n=37), those with ≥20 years but <30 years of experience 
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Table 1. Characteristics of survey responders
Item Value
Sex
  Female 23 (26.0)
  Male 67 (74.0)
Expertise
  Neurology 70 (78.0)
  Neurosurgery 3 (3.0)
  Pediatrics 17 (19.0)
Duration of experience (years) 16.6±8.22
  ≥30 7 (7.8)
  >30-20 27 (30.0)
  >20-10 37 (41.1)
  >10 19 (21.1)
Type of hospitals
  Primary 7 (8.0)
  Secondary 21 (23.0)
  Tertiary 37 (41.0)
  Quaternary 25 (28.0)
Residential area
  Seoul, Gyeonggi 59 (66.0)
  Chungcheong, Jeolla, Jeju 12 (13.0)
  Gyeonsang, Gangwon 19 (21.0)
Values are presented as mean±standard deviation or number (%).
for 30% (n=27), those with <10 years of experience for 21.1% 
(n=19), and those ≥30 years of experience for 7.8% (n=7). Those 
who worked mainly in tertiary and quaternary hospitals accounted 
for the most (68.9%, n=62), followed by those who worked in sec-
ondary hospitals (23.3%, n=21) and primary hospitals (8.9%, n=7). 
As for the working place locations, all provinces in Korea were 
included. Many of them were in Seoul and Gyeonggi (65.6%, n=59) 
(Table 1). 
Survey questionnaire development
The definition of DRE across survey items was developed referring 
to ILAE criteria. Overall survey questionnaires were composed of six 
items (Fig. 2). The first question asked about the percentage of treat-
ment failures for the two drugs or more. In addition, sub-questions 
asked about the distribution of lack of effect, adverse event, adher-
ence, and others for reasons judged to be uncontrolled causes. The 
second question was used to determine approximate rates of pa-
tients who failed five AEDs or more in the past, and the feasibility of 
efficacy on additional AEDs as a following question. In the third 
question, overall rates of patients treated with five AEDs or more cur-
rently and the possibility to be treated with additional AEDs were 
determined. The third question was developed through the number 
of AEDs with loss of seizure freedom rate14,21 and 2010 DRE severity 
proposal,22 as mentioned in the current evidence literature. The 
fourth item consisted of priorities with factors such as mechanism of 
action, hepatic enzyme inducer, pharmacokinetic interaction, ad-
verse events, and others when adding AEDs to those who had con-
trol failures with five AEDs or more in the past. The fifth question was 
about the importance of factors considering additional AED among 
the options: expert opinions, meta-analysis, textbook, clinical trials, 
reimbursement guideline, and others. The fifth question asked to list 
those options in order depending on the degree of importance. The 
final question asked about satisfaction rate on overall AED re-
imbursement system of HIRA with the range of 100 points and 5 
scales.
Survey questionnaires
The primary objective of this survey was to evaluate the pre-
scription pattern of AED for DRE patients treated with multiple AEDs 
in real world practice. We created the survey questionnaires concern-
ing previous numbers of AEDs, factors for the next AED choice, and 
feasibility to reduction in seizure frequency for each patient. The sur-
vey includes questionnaires: 1) the proportion of patients who failed 
two AED treatments, 2) the reason for failure to achieve seizure re-
duction, 3) rates of patients experienced from five AEDs or more prior 
(with previous prescription), 4) the feasibility to achieve seizure con-
trol when adding AEDs, 5) the proportion of patients who failed five 
AED treatments or more (currently prescribed), 6) the feasibility to 
seizure control for the patients who failed five AEDs or more, 7) the 
importance of factors considering additional AED, 8) priorities of evi-
dence for further AED prescription on those who failed to five AEDs 
or more, 9) and 10) satisfaction with AED reimbursements from HIRA 
government body (Table 1).
Analysis and statistics
The survey conducted with a total of 108 eligible responses, and 
results were collected via e-mail or replies with attachment. Data 
analyses were conducted in a descriptive way. To assess detailed 
items, all questions were computed with response rates individually. 
Among ranking responses at question number 4 and 5, rank 4 was a 
cut-off value. For sub-analysis, the Kruskal-Wallis test was used as a 
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Figure 2. Survey form about anti-epileptic drug medication.
nonparametric statistical method. Overall data were divided by expe-
rience, region, hospital level, and expertise to confirm the statistical 
significance of each question. All analyses were performed using R 
program (version 4.0.5; R Foundation for Statistical Computing, 
Vienna, Austria).
Results
The proportion of patients who failed two AEDs or 
more and reasons of failure to seizure control
The mean proportion of patients who failed in two AED treatments 
was 26.9±11.50% (range from 2% to 70%). The causes of the fail-
 Sunwoo JS, et al. Survey on Ant-Epileptic Drug Therapy 77
www.kes.or.kr
Table 2. Results of survey on items of drug failure and national insurance
Value
Q1. The proportion of two drug failure (including secondary monotherapy and combination therapy) (%) 26.9±11.50
  Q1-1. Reasons of failure
    Efficacy 57.4%
    Adverse events 20.4%
    Adherence 18.6%
    Others 3.6%
Q2. The proportion of five drug failure (including past medications) (%) 13.3±9.48
  Q2-1. Expectation of efficacy in additional add-on therapy
    Positive 23 (54.5)
    Negative 20 (45.5)
Q3. The proportion of five drug failure in current medications (%) 7.3±5.30
  Q3-1. Expectation of efficacy in additional add-on therapy 
    Positive 14 (37.9)
    Negative 29 (62.1)
Q4. Satisfaction on national medical insurance on anti-epileptic drug medications
  Q4-1. Overall satisfaction score (on a scale from 1 to 100) 64.9±16.91
  Q4-2. Proportion according to degree of satisfaction
    Very satisfied 19 (1.1)
    Satisfied 11 (28.1)
    Neutral  9 (38.2)
    Dissatisfied  4 (23.6)
    Very dissatisfied 0 (9.0)
Values are presented as mean±standard deviation or number (%) unless otherwise indicated.
ure included lack of efficacy (57.4%), adverse event (20.4%), adher-
ence (18.6%), and others (3.6%) (Table 2). In sub-analysis groups, 
long clinical experienced epileptologists tended to report higher pro-
portion of two drug failure than short clinical experienced ones, but 
not statistically significant. Regardless of expertise, hospital in-
stitution, clinical experience, or region, the main reason for treatment 
failure was ‘lack of efficacy’. Among reasons of failure, neurology ex-
perts were likely to consider ‘adverse event’ and ‘adherence’ than 
the others even though it was not statistically significant.
Rates of patients experiencing five AEDs prior or 
more (with previous prescriptions) and feasibility 
to seizure control when adding AEDs
The mean proportion of patients experienced five AEDs or more, 
including previous medications, was 13.3±9.48% (range, 1% to 
60%). When asked about possible control of seizures in these pa-
tients by adding AED further, 48 epileptologists (54.5%) responded 
that it was feasible (Table 2). Regarding intractable proportion of five 
drug failure, results based on the expertise showed that the pro-
portion was 13.9% in neurologists, 12.4% in pediatricians, and 
5.7% in neurosurgeon. As per clinical experience analysis, results are 
shown below: <10 years, 12.4%; 10-20 years, 12.4%; 20-30 years, 
13.6%; and ≥30 years, 12.7%. In a geographic analysis, the results 
of Seoul, Gyeonggi (11.8%, n=56), Chungcheong, Honam, Jeju 
(16.5%, n=12), Gyeonsang, and Gangwon (17.1%, n=19) did not 
show significant difference. Regarding the question about the feasi-
bility of seizure control with additional AEDs by expertise, those with 
neurology (59.4%), pediatrics (43.8%), and neurosurgery (0.0%) ex-
pertise responded that it was feasible. Depending on the medical in-
stitution, the positive response was 28.6% in primary hospital, 
57.1% in secondary hospital, 52.8% in tertiary hospital, and 62.5% 
in quaternary hospital.
The proportion of patients failed five AED 
treatments or more (currently prescribed) and the 
feasibility to achieve seizure control when adding 
AEDs
The mean proportion of patients currently taking five AEDs or 
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Table 3. Results of survey on selection priority of antiepileptic drug medications in refractory patients (survey question number Q4)
Item
Ranking
1st 2nd 3rd 4th
Mechanism of action 72 (91.1) 3 (3.8) 1 (1.3) 3 (3.8)
Hepatic enzyme inducer 0 (0.0) 10 (12.7) 28 (35.4) 39 (49.4)
Other pharmacokinetic event 0 (0.0) 20 (25.3) 33 (41.8) 25 (31.6)
Adverse drug event 6 (7.6) 46 (58.2) 17 (21.5) 10 (12.7)
Others 1 (1.3) 0 (0.0) 0 (0.0) 2 (2.5)
Total 79 79 79 79
Values are presented as number (%).
Table 4. Results of survey on referential resources (survey question number Q5)
Item
Ranking
1st 2nd 3rd 4th
Expert opinion 23 (31.5) 15 (20.5) 10 (13.7) 11 (15.1)
Meta-analysis 4 (5.5) 7 (9.6) 13 (17.8) 22 (30.1)
Textbook  9 (12.3) 7 (9.6)  9 (12.3)  9 (12.3)
Review, case series 10 (13.7) 14 (19.2) 13 (17.8) 12 (16.4)
Guidelines 13 (17.8) 12 (16.4) 12 (16.4) 7 (9.6)
Clinical experience 14 (19.2) 15 (20.5) 12 (16.4) 7 (9.6)
Medical insurance 0 (0.0) 3 (4.1) 3 (4.1) 5 (6.8)
Others 0 (0.0) 0 (0.0) 1 (1.4) 0 (0.0)
Total 73 73 73 73
Values are presented as number (%).
more was 7.3±5.30% (Table 2). In sub-analyses based on expertise, 
the rate was 7.6% in neurologist, 6.9% in pediatrician, and 2.3% in 
neurosurgeon. The result of the question “could benefit from more 
additional AEDs” was 37.9% in “yes” response (Table 2). As per 
clinical experience analysis, results are shown below: <10 years, 
16.7%; 10-20 years, 51.4%; 20-30 years, 28%; and ≥30 years, 
57.1%. Depending on the medical institution, the positive answer 
was 0.0% in primary hospital, 28.6% in secondary hospital, 31.4% 
in tertiary hospital, and 64.0% in quaternary hospital. In the detailed 
results asking the possibility of efficacy with additional AEDs, neurol-
ogy (40.3%, n=67) and pediatrics (35.3%, n=17) showed similar re-
sults while neurosurgery (0.0%, n=3) had extremely low result. 
The importance of factors considering additional 
AEDs
For patients failed to five AEDs or more, the following factors were 
considered as priorities: 1) mechanism of action, 2) adverse event, 3) 
other pharmacokinetics, and 4) liver metabolism derivatives in order 
(n=79) (Table 3). Other factors included patient's underlying disease, 
bioavailability, protein binding, and knowledge of the latest papers 
on AEDs. Regardless of type of expertise, medical institution, clinical 
experience and region, mechanism of action was top considered op-
tion in 72 responders (91.1%), followed by adverse event which was 
considered by six (7.6%).
The priorities of evidence for further AED 
prescription on those who failed to five AEDs
Under the same conditions, when it came to considering adding 
more AEDs, expert opinion was considered as top priority by re-
spondents, followed by clinical experience, reimbursement guide-
lines, and clinical evidences in order from given items including ex-
pert opinion, meta-analysis, textbook, clinical experience, reimburse-
ment guidelines, clinical evidences, and others (Table 4). The expert 
opinion was shown as top priority by 23 responders (31.5%), fol-
lowed by clinical experience in 14 (19.2%), guidelines in 13 (17.8%), 
clinical evidences such as review article and case reports in 10 
(13.7%), and the others in 13 (17.8%). In the detailed analysis, the 
best considered item was “expert opinion” in those with neurology 
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and pediatrics expertise, while “clinical evidences and clinical experi-
ences” was chosen for those with expertise in neurosurgery. Expert 
opinion was also reported as the top priority according to res-
ponder’s clinical experiences and regions.
Satisfaction with AED reimbursements system from 
HIRA government body
Overall average points for satisfaction on HIIRA reimbursement 
system for AED as 64.9±16.91 points (range, 0 to 100) with very sat-
isfied in one responder (1.1%), satisfied in 25 (27.8%), neutral in 34 
(37.8%), dissatisfied in 22 (24.4%), and very dissatisfied in eight 
(8.9%) in detail (Table 2).
Discussion
This survey targeted epilepsy experts prescribing AEDs to establish 
a comprehensive opinion on the prescribing status of epilepsy pa-
tients, especially DRE patients and factors to consider when perform-
ing AED selection. It was the first trial conducted with 108 experts in 
epilepsy nationwide. These experts had a great deal of experience in 
prescribing AED with clinical experiences in epilepsy clinic for at least 
1 year. The place of participants consisted of all provinces in Korea. 
The e-mail survey was sent to responders to complete the survey file 
as attachment or reply with answers. It was conducted from February 
2021 to March 2021. The survey participants showed a high re-
sponse rate of 83% during a short period of 4 weeks.
Drug resistance in epilepsy is common. In AED treatment of newly 
diagnosed epilepsy patient, the seizure free rate of initial mono-
therapy is nearly about 60%. The remaining patients are considered 
to become potentially DRE because the further seizure free rate in ad-
ditional changed or combined AED therapy is less than 10%. 
Historically comparative polytherapy trials have found that 11% to 
35% of patients with partial seizures become seizure free, and addi-
tional 12% to 29% of patients have more than 50% seizure 
reduction.22-25 A review of 35 seizure studies showed that the pooled 
prevalence proportion of DRE was 30%.26 In the present study, fail-
ure rate of two drugs was about 26.9±11.50%, in line with approx-
imate rate of the previous data following the ILAE criterion for DRE.26 
In the present study, the proportion of patients who failed five AEDs 
or more including history was 13.3±9.48%. There was a subsequent 
question on whether additional AED treatment could help seizure 
control even in the failed cases with five failed AEDs or more prior. 
About 55% of responders said that the treatment would be effective 
if adding another AED to them. This reveals that there is still room for 
new AED trial even in DRE with five previous failed drugs or more. In 
sub-analysis, it was confirmed that 59.4% of neurologist and 57.1% 
of those with clinical experience ≥30 years responded hopefully, in-
dicating that neurology subspecialty and longer clinical experience 
tended to answer positively. Korean National Evidence-based Healthcare 
Collaborating Agency has reported that the percentage of AED 1 year 
before epilepsy surgery is 20.3% for those having ≤2 drugs, 28.3% 
for those having three drugs, 26.0% for those having four drugs, 
and 25.4% for those having ≥5 drugs (Chung CK, Lee JA; 
https://www.medric.or.kr; December 2015). In this Korean report, 
analysis of 1,443 refractory epilepsy patients who had undergone 
epilepsy surgery showed nearby two times higher percentage of pa-
tients on five drugs or more.
In the present study, the percentage of patients taking five failed 
AEDs or more currently at the same time was 7.3±5.30%. The rate of 
responding that the treatment would be effective when another AED 
was added was 37.9% (62.1% of 'No'). Considering positive think-
ing in more than one third of responders, an additional drug trial 
would be possible even for patients with five concurrent failed drugs 
or more. In sub-analysis, the majority (57.1%) of those with ≥30 
years of clinical experience answered that it would be effective, while 
only 16.7% of those with <10 years of clinical experience mentioned 
that it would be effective. Depending on the medical institution and 
clinical experience, 100% of those in the primary hospital reported 
that it would not be effective, whereas 64% of them from quaternary 
hospital responded positively. Considering above results, a new drug 
trial in DRE could be much influenced by service level of the hospital 
and the degree of clinical experience.
In the present study, the reason for intractability in the patients 
with two failed AEDs medications was the lack of effectiveness in 
majority of respondents (57.4%). Next to ineffectiveness, adverse 
events (20.4%) and non-adherence (18.6%) were common causes 
of intractability. The most common factor that leads to AED failure for 
seizure control in patients with DRE was lack of effectiveness. This 
suggests that even though there are currently 18 kinds of AEDs on 
the market in Korea, there are still unmet needs for new AEDs in real 
practice. Moreover, if drugs with new act mechanisms are developed, 
they might be able to achieve better efficacy in patients despite their 
previous exposure to various AEDs. Combination therapy with new 
AED having newly acting mechanism is likely to become popular be-
cause it is difficult to alleviate the number of seizures with currently 
existing AEDs. Thus, conventional two drug criteria for DRE cannot be 
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practical. Studies in developing countries have shown non-adher-
ence to anti-seizure medications occurs in 48.1-65.4%.27,28 Common 
causes of non-adherence are forgetfulness, the inability to obtain 
medication, and medication belief. Socioeconomic factors are sig-
nificantly related to adherence.28 In Korea, the national health in-
surance system is established well enough to lower the adherence 
issue. However, 20% of the DRE patients still had a drug adherence 
problem. Gollwitzer et al.29 have shown that good adherence is high-
er in patients with new than old, branded than generic AED, and 
once than two or more daily dosages. Thus, detailed counselling, se-
lection of AED and dose regimen can be needed in every day practice 
to reduce non-adherence as a cause of intractability.
In the present study, when adding drugs to patients whose seiz-
ures were not controlled despite the use of five AEDs in the past, 
“mechanism of action” was the first priority, followed by “adverse 
event”, “pharmacokinetics”, and “hepatic metabolism”. The per-
centage of selecting “mechanism of action” was absolutely high 
(91.1%). According to expertise, medical institution, clinical experi-
ence, and region, results have no significant changes. To make poly-
therapy efficacious, the combination should focus on synergistic ef-
fects with safety and without toxicity. These results of this survey con-
firmed that experts’ AED selection was identical to that shown in sev-
eral well-known references, textbooks, and guidelines.30-33
As in the epilepsy textbook, tailored AED selection for the optimal 
treatment is based on the individual condition of each patient as well 
as traditional epilepsy syndrome or seizure type. The impact of seiz-
ure can be different depending on individual patient. Thus, the differ-
ent impacts may induce different disease/therapy-associated alter-
ations that can affect intrinsic severity as well as seizure frequency. 
The disease/therapy-associated alterations include molecular, cel-
lular, and network changes and disease modifying effects (anti-in-
flammation, AED metabolism or distribution, change of efflux trans-
port P-glycoprotein).34 In the context of DRE, putative drug-resist-
ance mechanism and various factors including genetic factors should 
be considered according to the state of patients, because those fac-
tors are closely associated with seizure frequency of each patient. 
Add-on strategies in DRE might be considered, including the devel-
opment of novel approaches to help patients to overcome DRE. Our 
survey results reflect recent concepts that mechanistic polytherapy of 
AED continues to be common practice, especially in institutionalized 
epilepsy patients. In addition, Korean experts positively think that 
new AED could be tried for patients who have failed five or more 
AEDs to increase the efficacy of polytherapy.
However, the necessity of AED polytherapy is not needed for all 
patients. Especially for the elderly, women of child-bearing potential, 
and children, AED overtreatment should be avoided since they are 
vulnerable to undesirable combinations of AED and non-AED poly-
therapy and subsequent adverse effects posing significant risks.35-37 
In polytherapy, fatigue, dizziness, cognitive problems, memory com-
plaints, depression, suicidal attempt, and sudden unexplained death 
in epilepsy patients (SUDEP) can be increased due to pharmacoki-
netic interactions, dose-related neurotoxic effects, pharmacodynamic 
reactions, additive or synergistic drug related toxicities, and 
teratogenicity.36-40 Polytherapy may be less tolerable than mono-
therapy because of a higher total drug load.41,42 One study suggested 
that the appropriate indications for AED polytherapy can include 
transitional polytherapy during titration of a new adjunctive AED to-
ward monotherapy or long-term maintenance AED polytherapy in 
medically refractory epilepsy.43 Add-on therapy can also be tried for 
safety referring to the defined daily dose (DDD) values of the AEDs 
assigned by the World Health Organization. It has been reported that 
total daily dose is not controlled in most polytherapy studies.42,44 The 
prescribed daily dose to DDD ratio in monotherapy or polytherapy 
should be below 2 to reduce the likelihood of neurological side 
effects. In the present study, adverse event was the second priority 
following mechanism of action. It would be necessary to select an 
AED with improved adverse event. An optimal mechanism of action 
should also be given priority considering individual state of the 
patient. In this survey, next top priority was drug-drug interaction, 
which was derived from pharmacokinetic characteristics between 
AEDs. Experts preferred the evolutionary pharmacokinetic AED, low-
er hepatic metabolism (CYP450) regarding other medicine’s inter-
action and special population in epilepsy. In the present survey, 
Korean epileptologists referred to expert opinion, clinical experience, 
clinical trials, and guidelines in order when additional AED is added 
to patients. As shown the result, experts were likely to prefer cumu-
lative expert opinion rather than others since there was no unified 
opinion on personalized epilepsy patients.
Currently, 30 kinds of AEDs have been developed for decades. In 
Korea, 18 kinds of AEDs could be reimbursed. For epilepsy patients, 
customized precision medicine is essential based on individual seiz-
ure types and drug-related factors. From an epilepsy pathology point 
of view, it is a priority to select an AED with a suitable mechanism of 
action tailored to the patient in near future. In the case of recently de-
veloped third-generation drugs, brivaracetam (SV2A antagonist) and 
eslicarbazepine (persistent sodium channel blocker) have been de-
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veloped and they show advanced mode of actions. AEDs having new 
mechanisms of action are also under development. They will be in-
troduced in the near future. They are expected to contribute to per-
sonalized medicine for each patient based on clinical perspective.
In summary, we investigated how experts would approach, diag-
nose, and prescribe appropriate drugs to patients with refractory epi-
lepsy in Korea. Medical staffs with a lot of clinical experience have 
positive mind about the treatment of most DRE. Results confirmed 
that DRE could be approached with a method centering on the mech-
anism of action of a drug. If the standards for DRE patients were 
changed from two AEDs to not less than five including the past, not 
less than five drugs currently, there was a tendency of drug failure 
rate to decrease from 26.9% to 13.3% and 7.3%, although there 
was no significant difference according to the characteristics of the 
respondents. In addition, many respondents affirmed that adding 
AEDs would have a positive effect even if patients had treatment fail-
ure with five AEDs. The mechanism of action of the AED as a factor 
for additional selection was considered first. Most epileptologists re-
fer to the opinions of experts first. However, their satisfaction with 
the reimbursement system for the use of AEDs in the medical field 
seems to be limited to active treatment. The results of this survey are 
expected to contribute to the therapeutic significance, prognosis and 
future treatment considerations of Korean DRE patients in real clin-
ical practice.
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